Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) submitted its Monthly Return for Equity Issuer covering the period ended 30 April 2026. Key points are as follows:

• Stable authorised share capital: The company’s authorised and registered share capital held steady at RMB 456.82 million, comprising 420.29 million H shares listed in Hong Kong and 36.53 million unlisted ordinary shares, all with a par value of RMB 1.

• No movements in issued shares: Issued H shares remained unchanged at 420.29 million. Unlisted shares also stayed flat at 36.53 million. The company held no treasury shares, and there were no repurchases, cancellations, allotments or other alterations during the month.

• Public float remains adequate: Innogen Pharmaceutical confirmed compliance with the Main Board’s minimum 25 % public float requirement for its H shares as at 30 April 2026.

• No outstanding equity-linked instruments: The filing records no share option schemes, warrants, convertibles or other arrangements that could lead to future share issuance.

The return was authorised by Joint Company Secretary Yang Dongyan and filed with Hong Kong Exchanges and Clearing Limited on 6 May 2026.